- Home
- Europe Leber Congenital Amaurosis Market
Europe Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-497 | No of pages: 238 | Format:
Europe leber congential amaurosis market is projected to register a CAGR of 5.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
Europe Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe leber congential amaurosis market are:
Genetic advances in the diagnosis of LCA
Rising chronic disease
Market Players:
The key market players for Europe leber congential amaurosis market are listed below:
Invitae Corporation
Spark Therapeutics, Inc.
CENTOGENE N.V.
Allergan
CENTOGENE N.V.
Novartis AG
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 44 1.1 OBJECTIVES OF THE STUDY 44 1.2 MARKET DEFINITION 44 1.3 OVERVIEW OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET 44 1.4 LIMITATIONS 45 1.5 MARKETS COVERED 46 2 MARKET SEGMENTATION 49 2.1 MARKETS COVERED 49 2.2 GEOGRAPHICAL SCOPE 50 2.3 YEARS CONSIDERED FOR THE STUDY 51 2.4 CURRENCY AND PRICING 51 2.5 DBMR TRIPOD DATA VALIDATION MODEL 52 2.6 MULTIVARIATE MODELLING 55 2.7 DISEASE TYPE LIFELINE CURVE 55 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56 2.9 DBMR MARKET POSITION GRID 57 2.10 MARKET END USER COVERAGE GRID 58 2.11 VENDOR SHARE ANALYSIS 59 2.12 SECONDARY SOURCES 60 2.13 ASSUMPTIONS 60 3 EXECUTIVE SUMMARY 61 4 PREMIUM INSIGHTS 64 4.1 PIPELINE ANALYSIS FOR EUROPE LEBER CONGENTIAL AMAUROSIS MARKET 66 4.2 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 68 4.3 PESTEL ANALYSIS 71 4.4 PORTERS FIVE FORCES 72 5 EPIDEMIOLOGY 73 6 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 74 6.1 DRIVERS 76 6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 76 6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 79 6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 85 6.2 RESTRAINTS 86 6.2.1 LACK OF QUALIFIED PROFESSIONALS 86 6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 87 6.3 OPPORTUNITIES 88 6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 88 6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 88 6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 89 6.4 CHALLENGES 90 6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 90 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 90 7 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 91 7.1 OVERVIEW 92 7.2 INFANTILE TYPE 95 7.3 JUVENILE TYPE 95 7.4 OTHERS 96 8 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 97 8.1 OVERVIEW 98 8.2 THERAPY 101 8.2.1 GENE THERAPY 102 8.2.1.1 LUXTURNA 102 8.2.2 RETINAL PROSTHETIC 102 8.2.3 NEUROPROTECTIVE AGENTS 102 8.2.3.1 VITAMIN A PALMITATE 103 8.2.3.2 DOCOSAHEXAENOIC ACID 103 8.2.3.3 LUTEIN 103 8.2.3.4 OTHERS 103 8.2.4 OTHERS 103 8.3 DIAGNOSIS 104 8.3.1 CLINICAL DIAGNOSIS 105 8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 105 8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 106 8.3.1.1.2 DARK ADAPTOMETRY (DA) 106 8.3.1.2 RETINAL IMAGING 106 8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 106 8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 107 8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 107 8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 107 8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 107 8.3.1.3 VISUAL FIELD TEST 107 8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 107 8.3.1.3.2 MANUAL FIELD TEST 107 8.3.1.4 CLINICAL EYE EXAMINATION 108 8.3.1.4.1 SLIT LAMP 108 8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 108 8.3.1.4.3 REFRACTION TEST 108 8.3.1.4.4 DILATION EXAM 108 8.3.1.5 OTHERS 108 8.3.2 GENETIC DIAGNOSIS 109 9 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 110 9.1 OVERVIEW 111 9.2 HOSPITALS 114 9.3 SPECIALITY CLINICS 115 9.4 AMBULATORY SURGICAL CENTERS 116 9.5 HOME HEALTHCARE 117 9.6 OTHERS 118 10 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 119 10.1 OVERVIEW 120 10.2 RETAIL SALES 123 10.2.1.1 HOSPITAL PHARMACIES 124 10.2.1.2 RETAIL PHARMACIES 124 10.2.1.3 OTHERS 124 10.3 DIRECT TENDER 124 11 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 125 11.1 EUROPE 126 11.1.1 GERMANY 133 11.1.2 FRANCE 137 11.1.3 U.K. 141 11.1.4 RUSSIA 145 11.1.5 ITALY 149 11.1.6 SPAIN 153 11.1.7 NETHERLAND 157 11.1.8 SWITZERLAND 161 11.1.9 POLAND 165 11.1.10 TURKEY 169 11.1.11 AUSTRIA 173 11.1.12 HUNGARY 177 11.1.13 NORWAY 181 11.1.14 IRELAND 185 11.1.15 LITHUANIA 189 11.1.16 REST OF EUROPE 193 12 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 194 12.1 COMPANY SHARE ANALYSIS: EUROPE 194 13 SWOT ANALYSIS 195 14 COMPANY PROFILE 196 14.1 SPARK THERAPEUTICS, INC 196 14.1.1 COMPANY SNAPSHOT 196 14.1.2 COMPANY SHARE ANALYSIS 196 14.1.3 PRODUCT PORTFOLIO 197 14.1.4 RECENT DEVELOPMENT 197 14.1.4.1 EU AUTHORIZATION 197 14.2 OPTOS 198 14.2.1 COMPANY SNAPSHOT 198 14.2.2 COMPANY SHARE ANALYSIS 198 14.2.3 PRODUCT PORTFOLIO 199 14.2.4 RECENT DEVELOPMENT 199 14.2.4.1 PRODUCT APPROVAL 199 14.3 CD GENOMICS 200 14.3.1 COMPANY SNAPSHOT 200 14.3.2 COMPANY SHARE ANALYSIS 200 14.3.3 PRODUCT PORTFOLIO 201 14.3.4 RECENT DEVELOPMENT 201 14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 202 14.4.1 COMPANY SNAPSHOT 202 14.4.2 REVENUE ANALYSIS 202 14.4.3 COMPANY SHARE ANALYSIS 203 14.4.4 PRODUCT PORTFOLIO 203 14.4.5 RECENT DEVELOPMENTS 203 14.4.5.1 COLLABORATION 203 14.5 LKC TECHNOLOGIES, INC 204 14.5.1 COMPANY SNAPSHOT 204 14.5.2 COMPANY SHARE ANALYSIS 204 14.5.3 PRODUCT PORTFOLIO 205 14.5.4 RECENT DEVELOPMENT 205 14.5.4.1 PRODUCT APPROVAL 205 14.5.5 PRODUCT APPROVAL 205 14.6 AGTC 206 14.6.1 COMPANY SNAPSHOT 206 14.6.2 REVENUE ANALYSIS 206 14.6.3 PRODUCT PORTFOLIO 207 14.6.4 RECENT DEVELOPMENTS 207 14.6.4.1 AGREEMENT 207 14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 208 14.7.1 COMPANY SNAPSHOT 208 14.7.2 REVENUE ANALYSIS 208 14.7.3 PRODUCT PORTFOLIO 209 14.7.4 RECENT DEVELOPMENTS 209 14.8 ASTELLAS PHARMA INC. 210 14.8.1 COMPANY SNAPSHOT 210 14.8.2 REVENUE ANALYSIS 210 14.8.3 PRODUCT PORTFOLIO 211 14.8.4 RECENT DEVELOPMENT 211 14.9 ATSENA THERAPEUTICS 212 14.9.1 COMPANY SNAPSHOT 212 14.9.2 PRODUCT PORTFOLIO 212 14.9.3 RECENT DEVELOPMENT 212 14.10 CENTOGENE N.V. 213 14.10.1 COMPANY SNAPSHOT 213 14.10.2 REVENUE ANALYSIS 213 14.10.3 PRODUCT PORTFOLIO 214 14.10.4 RECENT DEVELOPMENT 214 14.10.4.1 PRODUCT LAUNCH 214 14.11 COAVE THERAPEUTICS 215 14.11.1 COMPANY SNAPSHOT 215 14.11.2 PRODUCT PORTFOLIO 215 14.11.3 RECENT DEVELOPMENT 215 14.12 EDITAS MEDICINE 216 14.12.1 COMPANY SNAPSHOT 216 14.12.2 REVENUE ANALYSIS 216 14.12.3 PRODUCT PORTFOLIO 217 14.12.4 RECENT DEVELOPMENTS 217 14.12.4.1 DATA & TRAIL DATA PRESENTATION 217 14.13 ELUMINEX BIOSCIENCES 218 14.13.1 COMPANY SNAPSHOT 218 14.13.2 PRODUCT PORTFOLIO 218 14.13.3 RECENT DEVELOPMENT 218 14.14 GYROSCOPE THERAPEUTICS LIMITED 219 14.14.1 COMPANY SNAPSHOT 219 14.14.2 PRODUCT PORTFOLIO 219 14.14.3 RECENT DEVELOPMENTS 219 14.15 INVITAE CORPORATION 221 14.15.1 COMPANY SNAPSHOT 221 14.15.2 REVENUE ANALYSIS 221 14.15.3 PRODUCT PORTFOLIO 222 14.15.4 RECENT DEVELOPMENTS 222 14.15.4.1 NEW FACILITY 222 14.15.4.2 EXPANSION 222 14.16 IVERIC BIO. 223 14.16.1 COMPANY SNAPSHOT 223 14.16.2 PRODUCT PORTFOLIO 223 14.16.3 RECENT DEVELOPMENT 223 14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 224 14.17.1 COMPANY SNAPSHOT 224 14.17.2 REVENUE ANALYSIS 224 14.17.3 PRODUCT PORTFOLIO 225 14.17.4 RECENT DEVELOPMENTS 225 14.18 MEIRAGTX LIMITED 226 14.18.1 COMPANY SNAPSHOT 226 14.18.2 PRODUCT PORTFOLIO 226 14.18.3 RECENT DEVELOPMENT 226 14.19 METROVISION 228 14.19.1 COMPANY SNAPSHOT 228 14.19.2 PRODUCT PORTFOLIO 228 14.19.3 RECENT DEVELOPMENT 228 14.19.3.1 FDA CLEARANCE APPROVAL 228 14.20 OCUGEN INC. 229 14.20.1 COMPANY SNAPSHOT 229 14.20.2 PRODUCT PORTFOLIO 229 14.20.3 RECENT DEVELOPMENT 229 14.21 OKUVISION 230 14.21.1 COMPANY SNAPSHOT 230 14.21.2 PRODUCT PORTFOLIO 230 14.21.3 RECENT DEVELOPMENTS 230 14.21.3.1 APPROVAL 230 14.22 PROQR THERAPEUTICS 231 14.22.1 COMPANY SNAPSHOT 231 14.22.2 PRODUCT PORTFOLIO 231 14.22.3 RECENT DEVELOPMENTS 231 14.23 REGENXBIO INC. 232 14.23.1 COMPANY SNAPSHOT 232 14.23.2 REVENUE ANALYSIS 232 14.23.3 PRODUCT PORTFOLIO 233 14.23.4 RECENT DEVELOPMENTS 233 14.24 SPARINGVISION 234 14.24.1 COMPANY SNAPSHOT 234 14.24.2 PRODUCT PORTFOLIO 234 14.24.3 RECENT DEVELOPMENTS 234 15 QUESTIONNAIRE 235 16 RELATED REPORTS 238Segmentation
Short Description Europe Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe) Industry Trends and Forecast to 2029 Market Definition: Leber congenital amaurosis (LCA) is a part of the spectrum of early-onset retinal dystrophy (EORD). It usually presents in the first few years of life, most often before the age of 1 year. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment. Market Segmentation: Europe leber congenital amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel. On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others. On the basis of type, the leber congenital amaurosis market is segmented into diagnosis and therapy. On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others. On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others. Market Players The key market players for Europe leber congenital amaurosis market are listed below: Invitae Corporation Spark Therapeutics, Inc. LKC TECHNOLOGIES, INC CENTOGENE N.V. Optos, Metrovision, Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics) CD Genomics ProQR Therapeutics OCUGEN, INC. MeiraGTx Limited Coave Therapeutics IVERIC bio, Inc. Atsena Therapeutics Editas Medicine Eluminex Biosciences Okuvision Astellas Pharma Inc. Allergan (A Subsidiary of Abbvie Inc.) AGTC Gyroscope Therapeutics Limited SparingVision Kubota Pharmaceutical Holdings Co. Ltd. REGENXBIO IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.